Viridian Therapeutics Inc

1S1

Company Profile

  • Business description

    Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

  • Contact

    221 Crescent Street
    Suite 103A
    WalthamMA02453
    USA

    T: +1 617 272-4600

    E: [email protected]

    https://www.viridiantherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    143

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,924.2245.760.58%
DAX 4024,569.7820.220.08%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,968.73101.711.15%
HKSE24,028.37136.050.57%
NASDAQ20,611.34192.870.94%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers